Jane (Zheng) Yang Almstead, the wife of Neil Almstead, our Chief Technical Operations Officer, is employed by us as a Principal Scientist, Analytical Development. For her services to the Company during fiscal 2025, Ms. Almstead received compensation of $263,133.98, comprised of base salary, equity awards in the form of restricted stock units (based on the grant-date fair value), company 401(k) matching contributions, group term life insurance premiums paid by the Company, and non-equity incentive compensation (paid in fiscal 2026 based on 2025 performance) and amounts under an employee-wide health incentive program. These amounts reflect the full grant-date fair value of equity compensation awarded in 2025 (computed in accordance with the provisions of ASC 718), and do not represent the actual value realized by the employee during the year. Ms. Almstead participated in our benefit programs generally available to U.S. employees during 2025. Dr. Almstead does not and did not participate in the compensation decisions by the Company regarding his family member, and we believe that the compensation paid to Ms. Almstead is fair and commensurate with what her compensation would be if she had no relationship to an executive officer of the Company. Consists of (a) 254,013 shares of common stock underlying options held directly by Dr. Almstead that are exercisable as of April 10, 2026 or will become exercisable within 60 days of such date; (b) 14,637 shares of common stock held directly by Dr. Almstead; and (c) 1,067 shares of common stock held by Dr. Almstead s spouse. Dr. Almstead disclaims beneficial ownership of shares held by his spouse.